Sai Life Sciences has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India.The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics.Maneesh Pingle, Head of Discovery Services, said: �The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients` evolving needs as they advance peptide therapies across diverse therapeutic areas.Powered by Capital Market - Live News

Net profit of Sai Life Sciences rose 35.95% to Rs 53.85 crore in the quarter ended December 2024 as against Rs 39.61 crore during the previous quarter ended December 2023. Sales rose 14.64% to Rs 439.78 crore in the quarter ended December 2024 as against Rs 383.63 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales439.78383.63 15 OPM %27.2325.11 - PBDT105.7484.35 25 PBT71.6552.94 35 NP53.8539.61 36 Powered by Capital Market - Live News

Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 6 February 2025.Powered by Capital Market - Live News

The equity shares of Sai Life Sciences (Scrip Code: 544306) are listed effective 18 December 2024 and admitted to dealings on the Exchange in the list of ``B`` Group Securities. Powered by Capital Market - Live News